Clinical trial · Interventional
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
NCT02293356CI-TRIAL-00018880unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more reasonable basis for clinical drug programs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nimotuzumab Injection | Drug | Nimotuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nimotuzumab Injection
- description
- 200mg,Once a week，Intravenous infusion over 60 minutes
- interventionNames
- Drug: Nimotuzumab Injection
Primary outcomes (1)
- measure
- To determine the safety of the treatment with Nimotuzumab(NCI Common Terminology Criteria for Adverse Events v4.03)
- timeFrame
- up to 30 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically or cytologically confirmed nasopharyngeal carcinoma 2. Sex and age without limiting 3. Treatment without limiting 4. Subjects with reproductive potential (males and females) willing to use reliable means of contraception 5. Able and willing to give written informed consent and comply with the requirements of the study protocol Exclusion Criteria: 1. Patients with severe allergies or idiosyncratic constitution 2. Women who are pregnant (determined by urine pregnancy test)or breast feeding 3. Any other severe complications or functional disorder of organ systems, which will affect the evaluation of safety of patients or will interfere with the test drug according to the researcher's point of view
References
Publications (0)
Data not yet available
No reference posted for this study.